#ASH18: Ac­celeron and Cel­gene take cen­ter stage with a pair of PhI­I­Is for lus­pa­ter­cept they be­lieve will back up $2B-plus in rev­enue pro­jec­tions

Ever since Ac­celeron and its needy part­ners at Cel­gene tout­ed pos­i­tive Phase III top-line re­sults for lus­pa­ter­cept for pa­tients suf­fer­ing from myelodys­plas­tic syn­drome as well as be­ta tha­lassemia, an­a­lysts have been try­ing to fig­ure out just how good the num­bers need to be in or­der to live up to the com­pa­nies’ es­ti­mates this drug will de­liv­er $2 bil­lion-plus in peak sales.

So you bet­ter be­lieve that their ap­pear­ance in the show­case ple­nary ses­sion at ASH on Sat­ur­day was keep­ing plen­ty of peo­ple on their toes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER